Public health groups raise concern on patent grant to promising, new HIV drug Patient and public health groups have raised concerns over a potential patent grant to Gilead Sciences for the HIV drug ...

IBBQ is a relatively new US biotech ETF that competes with established peers like IBB and XBI. Read why I don't recommend ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked ...

Ending Acquired Immune Deficiency Syndrome (AIDS) as a public health threat here by 2030 will take much effort as it will all around the world. The key, ...

Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...

There are now multiple forms of injectable PrEP medications. Lenacapavir, which is Gilead's injectable drug, differs from ...

Yuhan and Johnson & Johnson Innovative Medicine (JJIM), formerly known as Janssen, ended a research project after securing ...

In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...

Current INSTI vs protease inhibitor or NNRTI use is linked to an increased risk for diabetes, which is slightly attenuated when adjusted for changes in BMI.

Defendant Yisel Lopez has been found in contempt for violating an asset freeze order through the sale of property.